Clinical Trials
65 trialsNeoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
Shanghai Henlius Biotech
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
B2023-153
Sun Yat-sen University
ROME
Fondazione per la Medicina Personalizzata
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Zai Lab (Hong Kong), Ltd.
HIST-RIC
Institut Paoli-Calmettes
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Yantai Yuhuangding Hospital
VinCaT
National Cancer Institute, Naples
FB-12
NSABP Foundation Inc
NeoPATH
Ruijin Hospital
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
West China Hospital
HERES
Rigshospitalet, Denmark
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
ChineseAMS
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
ChineseAMS
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
HERMET
University of Kansas Medical Center
NeoTPPF
Fudan University
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
ChineseAMS
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Fudan University
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Pyramid
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer
Guangdong Provincial People's Hospital
B-DOCT
The Netherlands Cancer Institute
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
Shandong Cancer Hospital and Institute
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
SOBER
Ruijin Hospital
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
Ruijin Hospital
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Fuzhou General Hospital
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Peking University
Pyrotinib
Peking Union Medical College Hospital
HERACLES
Fondazione del Piemonte per l'Oncologia
NEOADAPT
Midwestern Regional Medical Center
HERZUMA-GC
Dong-A University Hospital
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
HERAKLES
Gangnam Severance Hospital
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
Xijing Hospital